First United Bank & Trust Reduces Position in Johnson & Johnson (NYSE:JNJ)

First United Bank & Trust cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 30.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,896 shares of the company's stock after selling 4,380 shares during the quarter. First United Bank & Trust's holdings in Johnson & Johnson were worth $1,641,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Lantz Financial LLC grew its holdings in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $453,000. Horan Securities Inc. lifted its position in shares of Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after purchasing an additional 90 shares during the period. Strategic Financial Concepts LLC lifted its position in shares of Johnson & Johnson by 57.9% in the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after purchasing an additional 1,271 shares during the period. Finally, State of Wyoming lifted its position in shares of Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on JNJ shares. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Bank of America dropped their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Raymond James dropped their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Up 0.9%

Shares of NYSE JNJ traded up $1.35 during trading on Thursday, hitting $156.61. The stock had a trading volume of 7,065,256 shares, compared to its average volume of 7,948,711. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market capitalization of $376.82 billion, a PE ratio of 23.55, a PEG ratio of 2.56 and a beta of 0.42. The firm has a fifty day moving average of $153.56 and a two-hundred day moving average of $153.70.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.32%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.